Eric K. Singhi, MD· @lungoncdoc · X·· 17 小时前评分90
正文 · 原文
WOW! BIG news for our patients with extensive-stage small cell lung cancer!
Phase 3 DeLLphi-305 trial, adding tarlatamab to durvalumab maintenance after initial chemoIO:
✅ OS: 21.1 vs 12.7 months (HR 0.42)
✅ PFS: 7.4 vs 1.9 months (HR 0.34)
Practice-changed! #ESMO26
384 浏览 · 13 赞 · 0 转发 · 1 回复
会议摘要
LBA3按 Presidential Symposium I 对上
Tarlatamab plus durvalumab (durva) vs durva as 1L maintenance (1LM) therapy following durva, platinum, and etoposide (1L durva + EP) in extensive-stage small cell lung cancer (ES-SCLC): Primary analysis of the phase 3 DeLLphi-305 trial
https://esmocongress.esmo.org#ESMO26 DeLLphi-305: tarlatamab+durva vs durva, 1L maintenance ES-SCLC ➡️ OS 21.1 vs 12.7 mo, HR 0.42 ➡️ PFS 7.4 vs 1.9 mo, HR 0.34 ➡️ CRS 49.6% (G3+ 0.4%) Amazing to be part of this practice-changing study on the global steering committee!! @LungCancerRx @OncoAlert @oncodaily在 X 查看被引用的帖子
帖内回复
- FJ ⭐️⭐️+⭐️@pistoto2017
@lungoncdoc What will you use for 2L?
来源：Eric K. Singhi, MD · x.com